Figure S3 from Purinostat Mesylate Is a Uniquely Potent and Selective Inhibitor of HDACs for the Treatment of BCR-ABL–Induced B-Cell Acute Lymphoblastic Leukemia

Authors :: Lijuan Chen
Ting Niu
Yiguo Hu
Haoyu Ye
Xing Deng
Liya Luo
Liping Gou
Yong Chen
Li Zheng
Heying Pei
Jianhong Yang
Shoujun Zheng
Zejiang Zhu
Zhuang Yang
Dongni Yi
Yuyao Yi
Fang Wang
Minghai Tang
Qiang Qiu
Linyu Yang
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Toxicity studies of PM.

Full Text Access

Tools